MET amplification is a common off-target signaling pathway in NSCLC bypassing drivers such as EGFR mutations or ALK fusions (Engelman et al. 2007, Piotrowska et al. 2018, Dagogo-Jack et al. 2020, Schoenfeld et al. 2020). This evidence concerns the gene MET and non-small cell lung carcinoma.